A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PARADIGM-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 Apr 2018 According to a Novartis media release, post hoc analysis results were published in the Journal of the American College of Cardiology: Heart failure (JACC-HF).
- 16 Apr 2018 According to a Novartis media release, post hoc analysis findings were published in The Lancet Diabetes & Endocrinology.
- 16 Apr 2018 Results published in the Novartis media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History